Latest news
EU Approves Sanofi's MenQuadfi for Infants as Young as 6 Weeks, Expanding Protection Against a Leading Cause of Acquired Deafness - The Hearing ReviewThe Hearing Review · Fri, 07 Aug 2026 00:18:45 GMTSanofi Wins EU Approval to Use MenQuadfi in Infants From Six Weeks - TipRanksTipRanks · Thu, 06 Aug 2026 13:00:18 GMTSanofi (NASDAQ: SNY) gets EU approval to use MenQuadfi in infants - Stock TitanStock Titan · Thu, 06 Aug 2026 10:06:45 GMTCould Sanofi’s (ENXTPA:SAN) Expanded Infant Vaccine Approval Reinforce Its Vaccines-Led Investment Story? - simplywall.stsimplywall.st · Wed, 05 Aug 2026 18:53:19 GMTSanofi’s MenQuadfi approval expanded to infants from six weeks in Europe - European Pharmaceutical ReviewEuropean Pharmaceutical Review · Tue, 04 Aug 2026 13:39:01 GMTSanofi’s MenQuadfi approved in the EU for younger infants - The Pharma LetterThe Pharma Letter · Tue, 04 Aug 2026 10:26:53 GMTSanofi: MenQuadfi vaccine approved in the EU from six weeks of age - ideal-investisseur.frideal-investisseur.fr · Tue, 04 Aug 2026 08:59:00 GMTSanofi Wins EU Nod to Use MenQuadfi in Infants From Six Weeks - TipRanksTipRanks · Tue, 04 Aug 2026 06:02:34 GMT